|1st October 2020||Susan Elizabeth Arnold||5,423||Exercise of derivative||$1.15||$6,236.45|
|21st August 2020||Jonathan P Mow||10,000||Exercise of derivative||$1.24||$12,400.00|
|14th August 2020||John P Sharp||5,000||Exercise of derivative||$1.69||$8,450.00|
|27th February 2020||Susan Elizabeth Arnold||5,423||Exercise of derivative||$1.15||$6,236.45|
|22nd November 2019||Clay Thorp||1,518,026||Grant/award etc.||$1.05||$1,599,999.40|
|6th September 2019||Jonathan P Mow||19,000||Exercise of derivative||$1.24||$23,560.00|
|21st August 2019||John P Sharp||10,000||Exercise of derivative||$1.69||$16,900.00|
|21st August 2019||John P Sharp||5,000||Exercise of derivative||$1.44||$7,200.00|
|1st July 2019||Clay Thorp||180||Open or private sale||$14.00||$2,520.00|
|1st July 2019||Clay Thorp||2,014||Open or private sale||$14.00||$28,196.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in 2002.